The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease
Alzheimer's Disease
The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
-
Local Institution - 0072, Fullerton, California, United States, 92835
Local Institution - 0091, Inglewood, California, United States, 90301
Local Institution - 0095, Irvine, California, United States, 92614
Local Institution - 0083, Palo Alto, California, United States, 94304
Local Institution - 0069, San Diego, California, United States, 92103
Local Institution - 0088, Denver, Colorado, United States, 80210
Local Institution - 0090, Fort Myers, Florida, United States, 33912
Local Institution - 0086, Hallandale Beach, Florida, United States, 33009
Local Institution - 0092, Jacksonville, Florida, United States, 32216
Local Institution - 0082, Sarasota, Florida, United States, 34239
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
60 Years to 85 Years
ALL
No
Bristol-Myers Squibb,
Bristol-Myers Squibb, STUDY_DIRECTOR, Bristol-Myers Squibb
2029-02-23